Bob Josefsberg
Corporate Officer/Principal chez Chamberlain Healthcare Public Relations
Profil
Bob Josefsberg is currently working as the Executive Vice President at Chamberlain Healthcare Public Relations.
Prior to this, he worked as the Head-Media at Karuna Therapeutics, Inc.
Postes actifs de Bob Josefsberg
| Sociétés | Poste | Début |
|---|---|---|
Chamberlain Healthcare Public Relations
 Chamberlain Healthcare Public Relations Miscellaneous Commercial ServicesCommercial Services Chamberlain Healthcare Public Relations provides public relations services to the healthcare industry. It offers data strategy and communications; message and content development; advocacy relations; consumer media campaigns; traditional and social media; spokesperson recruitment and management; issues and crisis management and national and grassroots programming. The company is headquartered in New York, NY. | Corporate Officer/Principal | - |
Anciens postes connus de Bob Josefsberg
| Sociétés | Poste | Fin |
|---|---|---|
| KARA THER | Public Communications Contact | 18/03/2024 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Chamberlain Healthcare Public Relations
Chamberlain Healthcare Public Relations Miscellaneous Commercial ServicesCommercial Services Chamberlain Healthcare Public Relations provides public relations services to the healthcare industry. It offers data strategy and communications; message and content development; advocacy relations; consumer media campaigns; traditional and social media; spokesperson recruitment and management; issues and crisis management and national and grassroots programming. The company is headquartered in New York, NY. | Commercial Services |
Karuna Therapeutics, Inc.
 Karuna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA. | Health Technology |
